John W. Davis, MD,FACS

Peer-Reviewed Articles

1. Leitao MM, Kreaden US, Laudone V, Park BJ, Pappou EP, Davis JW Rice DC, Chang GJ, Rossi EC, Hebert AE, Slee A, Gonen M. The RECOURSE Study: Long-term Oncologic Outcomes Associated with Robotically Assisted Minimally Invasive Procedures for Endometrial, Cervical, cOlorectal, lUng, or pRoState cancEr: a Systematic Review and meta-analysis. Ann Surg 277(3):387-396, 2023. e-Pub 2022. PMID: 36073772.
2. Thomas RD, Davis JW , Cuccaro PM, Gemeinhardt GL. Assessing associations between insecure income and US workers' health: An IPUMS-MEPS analysis. Soc Sci Med 309:115240, 2022. e-Pub 2022. PMID: 35985245.
3. Reisler JD, Ditmars FS, Davis JW . Addressing a National Health Crisis: A Student-Run Congestive Heart Failure Clinic for Underserved Patients. Acad Med 97(7):949-950, 2022. e-Pub 2022. PMID: 34469350.
4. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW , Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J Urol 208(1):26-33, 2022. e-Pub 2022. PMID: 35536141.
5. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW , Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 208(1):10-18, 2022. e-Pub 2022. PMID: 35536144.
6. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW , Eggener S, Horwitz EM, Kane CJ, Kirkby E, Lin DW, McBride SM, Morgans AK, Pierorazio PM, Rodrigues G, Wong WW, Boorjian SA. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol 208(1):19-25, 2022. e-Pub 2022. PMID: 35536148.
7. Davis JW . Seasonal events and journal milestones. BJUI Compass 3(4):259-262, 2022. e-Pub 2022. PMID: 35783594.
8. Redman AD, Bietz J, Davis JW , Lyon D, Maloney E, Ott A, Otte JC, Palais F, Parsons JR, Wang N. Moving persistence assessments into the 21st century: A role for weight-of-evidence and overall persistence. Integr Environ Assess Manag 18(4):868-887, 2022. e-Pub 2021. PMID: 34730270.
9. Ballantyne CM, Davis JW . Exercise and Mortality in Heart Disease Cohorts: Meta-Analysis to Augment Available Evidence. J Am Coll Cardiol 79(17):1701-1703, 2022. PMID: 35483758.
10. Davis JW , Wang B, Tomczak E, Chi-Fu C, Harmouch W, Reynoso D, Keiser P, Cabada MM. Prediction of the need for intensive oxygen supplementation during hospitalisation among subjects with COVID-19 admitted to an academic health system in Texas: a retrospective cohort study and multivariable regression model. BMJ Open 12(3):e058238, 2022. e-Pub 2022. PMID: 35361651.
11. Altok M, Demirel C, Kang HC, Choi H, John D, Inguillo IA, DDavis JW , Ward JF. Impact of MRI/US fusion-guided prostate biopsy on biopsy-naïve patients: A single urologist's experience. BJUI Compass 3(1):19-25, 2022. e-Pub 2021. PMID: 35475153.
12. Shapiro DD, Davis JW , Williams WH, Chapin BF, Ward JF, Pettaway CA, Gregg JR. Increased body mass index is associated with operative difficulty during robot-assisted radical prostatectomy. BJUI Compass 3(1):68-74, 2022. e-Pub 2021. PMID: 35475154.
13. Urkmez A, Demirel C, Altok M, Bathala TK, Shapiro DD,Davis JW . Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. J Urol 206(4):894-902, 2021. e-Pub 2021. PMID: 34100650.
14. Gregg JR, Borregales LD, Choi H, Lozano M, McRae SE, Venkatesan AM, Davis JW , Nogueras-Gonzalez GM, Pisters LL, Ward JF. Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. World J Urol 39(9):3259-3264, 2021. e-Pub 2021. PMID: 33454813.
15. Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW . Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology 155:144-151, 2021. e-Pub 2021. PMID: 33676955.
16. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW , Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol 18(6):337-358, 2021. e-Pub 2021. PMID: 33824525.
17. Albaeni A, Davis JW , Ahmad M. Echocardiographic evaluation of the Athlete's heart. Echocardiography 38(6):1002-1016, 2021. e-Pub 2021. PMID: 33971043.
18. Davis JW , Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. BMJ Open 11(6):e043714, 2021. e-Pub 2021. PMID: 34130955.
19. Davis JW . Re: Randomized Comparison of Techniques for Control of the Dorsal Venous Complex During Robot-assisted Laparoscopic Radical Prostatectomy. Eur Urol 79(5):702-703, 2021. e-Pub 2020. PMID: 33384201.
20. Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M,Davis JW , Chapin BF, Ross AE, Klein EA, Nyame YA. Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. Cancer 127(9):1425-1431, 2021. e-Pub 2021. PMID: 33721334.
21. Chang CM, McIntosh AG, Shapiro DD, Davis JW , Ward JF, Gregg JR. Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI?. BJUI Compass 2(3):188-193, 2021. e-Pub 2021. PMID: 35475129.
22. Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW , Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int 127(3):340-348, 2021. e-Pub 2020. PMID: 32357283.
23. Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW , Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer 127(5):720-728, 2021. e-Pub 2021. PMID: 33411364.
24. Beach MW, Kearns KL, Davis JW , Stutzman JR, Lee D, Lai Y, Monaenkova D, Kram S, Hu J, Lukas C. Stability Assessment of a Polymeric Brominated Flame Retardant in Polystyrene Foams under Application-Relevant Conditions. Environ Sci Technol 55(5):3050-3058, 2021. e-Pub 2021. PMID: 33550796.
25. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone N, Thompson TC, Pisters L, Troncoso P, Davis JW , Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol 79(2):298-306, 2021. e-Pub 2020. PMID: 33279304.
26. Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW , Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus 7(1):71-77, 2021. e-Pub 2019. PMID: 31076357.
27. Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW . The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance. J Urol 205(1):122-128, 2021. e-Pub 2020. PMID: 32718204.
28. Davis JW . Medicine in Mind, Healing at Heart: Big Data and Its Limits in Compassionate Care. J Am Board Fam Med 34(2):449-451, 2021. PMID: 33833018.
29. Davis JW , Virk F, Ahmad M. Acute infective endocarditis masquerading as septic shock with acute respiratory distress syndrome. Clin Case Rep 8(12):3149-3153, 2020. e-Pub 2020. PMID: 33363896.
30. Urkmez A, Ranasinghe W, Davis JW . Surgical techniques to improve continence recovery after robot-assisted radical prostatectomy. Transl Androl Urol 9(6):3036-3048, 2020. PMID: 33457277.
31. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW , Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F. Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precis Oncol 4:1228-1238, 2020. PMID: 35050780.
32. Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW , Chapin BF. Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. J Urol 204(4):748-753, 2020. e-Pub 2020. PMID: 32259468.
33. Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW , Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun 11(1):4279, 2020. e-Pub 2020. PMID: 32855410.
34. Tzeng CD, Teshome M, Katz MHG, Weinberg JS, Lai SY, Antonoff MB, Bird JE, Shafer A, Davis JW , Adelman DM, Moon B, Reece G, Prabhu SS, DeSnyder SM, Skibber JM, Mehran R, Schmeler K, Roland CL, Tran Cao HS, Aloia TA, Caudle AS, Swisher SG, Vauthey JN. Cancer Surgery Scheduling During and After the COVID-19 First Wave: The MD Anderson Cancer Center Experience. Ann Surg 272(2):e106-e111, 2020. PMID: 32675511.
35. Ranasinghe WKB, Brooks NA, Elsheshtawi MA, Davis JW , Bathala TK, Tang C, Troncoso P, Aparicio A, Tu SM, Pisters LL, Chapin BF. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126(16):3667-3673, 2020. e-Pub 2020. PMID: 32453443.
36. Coady KK, Burgoon L, Doskey C,Davis JW . Assessment of Transcriptomic and Apical Responses of Daphnia magna Exposed to a Polyethylene Microplastic in a 21-d Chronic Study. Environ Toxicol Chem 39(8):1578-1589, 2020. e-Pub 2020. PMID: 32388890.
37. Xu J, Chang WS, Tsai CW, Bau DT, Davis JW , Thompson TC, Logothetis CJ, Gu J. Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. Carcinogenesis 41(3):267-273, 2020. PMID: 31408512.
38. Gregg JR, Davis JW , Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology 138:91-97, 2020. e-Pub 2019. PMID: 31899230.
39. Ahlering T, Huynh LM, Kaler KS, Williams S, Osann K, Joseph J, Lee D, Davis JW , Abaza R, Kaouk J, Patel V, Kim IY, Porter J, Hu JC. Correction to: Unintended consequences of decreased PSA-based prostate cancer screening. World J Urol 38(3):807, 2020. PMID: 31332511.
40. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW , Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis 23(1):136-143, 2020. e-Pub 2019. PMID: 31455846.
41. Grummet J, Gorin MA, Popert R, O'Brien T, Lamb AD, Hadaschik B, Radtke JP, Wagenlehner F, Baco E, Moore CM, Emberton M, George AK, Davis JW , Szabo RJ, Buckley R, Loblaw A, Allaway M, Kastner C, Briers E, Royce PL, Frydenberg M, Murphy DG, Woo HH. "TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now. Prostate Cancer Prostatic Dis 23(1):62-65, 2020. e-Pub 2020. PMID: 31932659.
42. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW , Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2019. PMID: 31742674.
43. Xu J, Chang WS, Tsai CW, Bau DT, Xu Y, Davis JW , Thompson TC, Logothetis CJ, Gu J. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine 52:102616, 2020. e-Pub 2020. PMID: 31981976.
44. Li J, White PR, Roche B, Davis JW , Leighton TG. Underwater radiated noise from hydrofoils in coastal water. J Acoust Soc Am 146(5):3552, 2019. PMID: 31795704.
45. Efstathiou E, Davis JW , Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol 76(4):418-424, 2019. e-Pub 2019. PMID: 31176622.
46. Gouin T, Becker RA, Collot AG, Davis JW , Howard B, Inawaka K, Lampi M, Ramon BS, Shi J, Hopp PW. Toward the Development and Application of an Environmental Risk Assessment Framework for Microplastic. Environ Toxicol Chem 38(10):2087-2100, 2019. e-Pub 2019. PMID: 31233238.
47. Buffey K, Davis JW , Kram S, Lukas C, O'Connor JC, Hunter SE. Comment on "Degradation of the Polymeric Brominated Flame Retardant "Polymeric FR" by Heat and UV Exposure". Environ Sci Technol 53(18):11056-11057, 2019. e-Pub 2019. PMID: 31486638.
48. Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, Davis JW , Mohler JL, Trock BJ, Klein EA, Tosoian JJ, Hyndman ME, Bismar TA. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer Prostatic Dis 22(3):399-405, 2019. e-Pub 2018. PMID: 30542054.
49. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW , Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol 76(3):268-272, 2019. e-Pub 2019. PMID: 31128968.
50. Reichard CA, Nyame YA, Sundi D, Tosoian J, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Davis JW , Chapin BF. Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?. BJU Int 124(2):282-289, 2019. e-Pub 2019. PMID: 30653804.
51. Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW , Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol 2(3):257-264, 2019. e-Pub 2019. PMID: 31200839.
52. Ahlering T, Huynh LM, Kaler KS, Williams S, Osann K, Joseph J, Lee D, Davis JW , Abaza R, Kaouk J, Patel V, Kim IY, Porter J, Hu JC. Unintended consequences of decreased PSA-based prostate cancer screening. World J Urol 37(3):489-496, 2019. e-Pub 2018. PMID: 30003374.
53. Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW , Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer 125(3):391-397, 2019. e-Pub 2018. PMID: 30423193.
54. Davis JW . Los Seres Humanos Matter: A Hispanic Health Story from Texas. J Am Board Fam Med 32(1):115-117, 2019. PMID: 30610150.
55. Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW , Thompson TC, Kim J, Logothetis CJ, Wu X. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. Oncoimmunology 8(1):e1483303, 2019. e-Pub 2018. PMID: 30546938.
56. McCormick BZ, Mahmoud AM, Williams SB, Davis JW . Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J Urol 35(1):6-17, 2019. PMID: 30692719.
57. Altok M, Troncoso P, Achim MF, Matin SF, Gonzalez GN, Davis JW . Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates. Asian J Androl 21(6):598-604, 2019. PMID: 31115364.
58. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW , Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
59. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW . Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis 21(4):524-532, 2018. e-Pub 2018. PMID: 29988098.
60. Eissa A, Elsherbiny A, Coelho RF, Rassweiler J,Davis JW , Porpiglia F, Patel VR, Prandini N, Micali S, Sighinolfi MC, Puliatti S, Rocco B, Bianchi G. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol 70(5):462-478, 2018. e-Pub 2018. PMID: 29664244.
61. Demirel CH, Altok M, Davis JW . Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?. Asian J Androl 21(1):37-44. e-Pub 2018. PMID: 30178774.
62. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW , Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol 74(2):140-143, 2018. e-Pub 2018. PMID: 29656854.
63. Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW . Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol 74(1):107-114, 2018. e-Pub 2017. PMID: 29233664.
64. Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW . Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection. BJU Int 122(1):66-75, 2018. e-Pub 2018. PMID: 29446205.
65. Chapin BF, Nguyen JN, Achim MF, Navai N, Williams SB, Prokhorova IN, Wang X, Tapia EMLN, Davis JW , Troncoso P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis 21(2):221-227, 2018. e-Pub 2017. PMID: 29230008.
66. Li R, Petros FG,Davis JW . Extended Pelvic Lymph Node Dissection in Bladder Cancer. J Endourol 32(S1):S49-S54, 2018. PMID: 29774757.
67. Blanchard P, Davis JW , Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121(4):540-548, 2018. e-Pub 2017. PMID: 28941030.
68. Demirel HC, Davis JW . Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy and future directions. Turk J Urol 44(2):93-102, 2018. e-Pub 2018. PMID: 29511576.
69. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW , Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys 100(2):374-382, 2018. e-Pub 2017. PMID: 29229325.
70. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW , Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol 36(6):581-590, 2018. e-Pub 2017. PMID: 29185869.
71. Basourakos SP, Davis JW , Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121(1):69-76, 2018. e-Pub 2017. PMID: 28710901.
72. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW . A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol 36(1):13.e19-13.e25, 2018. e-Pub 2017. PMID: 28964658.

Invited Articles

1. Ghazi A, Bjurlin M, Link R, Porpiglia F, Davis JW . AUA 2021 Panel Discussion: Image guided surgery: a focus on simulation and planning in partial nephrectomy. AUA News, 2022.
2. Davis JW . Pelvic lymphocele post-radical prostatectomy: How to prevent and how to treat?. AUA News, 2022.
3. Davis JW . Section and Specialty Meetings: Welcoming all to the 101st South Central AUA Annual Meeting for 2022. AUA News, 2022.
4. Davis JW . Out of Office: How a urologist’s hobby progressed from photographing kids’ activities to urology meetings to wildlife. AUA News, 2022.
5. McCormick BZ, Mahmoud AM, Williams SB, Davis JW . Biochemical recurrence after radical prostatectomy: current status of its use as a treatment endpoint and early management strategies. Indian Journal of Urology 35:6-17, 2019.
6. Demirel CH, Altok M, Davis JW . Focal therapy for localized prostate cancer: is there a “middle ground” between active surveillance and definitive treatment?. Asian J Androl 44, 2018.
7. Demirel HC, Davis JW . Multiparametric magnetic resonance imaging: Overview of the technique, clinical applications in prostate biopsy, and future directions. Turk J Uro:93-102, 2018.
8. Li R, Petros FG, Davis JW . Extended Pelvic Lymph Node Dissection in Bladder Cancer. J Endourol:S49-S54, 2018.
9. Li R, Petros FG, Kukreja JB, Williams SB, Davis JW . Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol 57(Suppl 2):S155-S164, 2016. e-Pub 2016. PMID: 27995219.
10. Davis JW , Miki T, Akdas A, Watanabe H, Kirkali Z, Wang R, Babaian RJ. The International Prostate Forum Introduction and History. Asian J Androl 17(6):863, 2015. PMID: 26112490.
11. Davis JW , Kamat AM. Lymphadenectomy with Robotic Cystectomy. Curr Urol Rep 14(1):59-63, 2013. e-Pub 2012. PMID: 23138180.
12. Davis JW . Is Laparoscopy Extinct for Renal Surgery?. AUA News (The Official News Magazine of the American Urological Association) 17(8), 2012.
13. Pettaway CA, Davis JW . Contemporary management of penile carcinoma: Part 1: Overview of epidemiology, diagnosis, staging and management of the primary tumor. AUA Update Series 2012 Volume 31(Lesson 15), 2012.
14. Davis JW . Circulating tumor cell assays for the prognosis of prostate and colon cancers. Expert Opin Med Diagn 3(3):293-301, 2009. e-Pub 2009. PMID: 23488464.
15. Davis JW , Shaves ME, Schellhammer PF. Contemporary management of prostate cancer with lethal potential. Oncology (Williston Park) 18(7):811-20; discussion 820-4, 829-32, 2004. PMID: 15255168.
16. Davis JW , Chang SS, Schellhammer PF. Clinical Trials Methodology. AUA Update Series 23/18, 2004.
17. Schellhammer PF,Davis JW . An evaluation of bicalutamide in the treatment of prostate cancer. Clinical Prostate Cancer 2/4:213-219, 2004.
18. Davis JW , Fabrizio MD. What's new with stents and wires. Contemporary Urology 10/29:29-41, 2000.

Manuals, Teaching Aids, Other Teaching Publications

1. . Prostate Cancer Education: "Prostate Cancer Survivorship: Surgical Management of Prostate Cancer and Late Effects of Surgery". 1 hour video presentation with slides/CME credit and questions. For: the CPRIT Survivorship Grant. Lewis Foxhall, PI, 2012.
2. Davis JW, McCammon KA, Schellhammer PF, Jordan GH. Complications of Radical Prostatectomy, 2006.
3. Davis JW. Obtaining a Surgery Residency - A Guide for University of Virginia Medical Students. Local, 1994.

Other Articles

1. Davis JW, Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 67(6):e126, 2015. PMID: 24484606.
2. Davis JW, Killick E, Tymrakiewicz M, Cieza-Borrella C, et al. Telomere length shows no association with BRCA1 and BRCA2 mutation status. PLoS One 9(1):e86659, 2014. PMID: 24489760.
3. Davis JW, et al Web-linked publication of the appendix to Davis et al in J Urol. J Urol 185:79-83, 2011.
4. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, et al Bacillus Calmette-Guerin with or without interferon a2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 184:1915-1919, 2010.
5. Davis JW, et al Web-linked publication of the appendix to Davis, et al. BJU Int 105:1148-1154, 2009.

Editorials

1. Davis JW . Shining a little light on peer review debates. BJUI Compass 3(5):319-323, 2022. PMID: 35950039.
2. Davis JW . 2022 May Editorial: 'The Unfair Reviewer Comments'. BJUI Compass 3(3):193-196, 2022. PMID: 35492228.
3. Davis JW . Adapting to the long pandemic. BJUI Compass 3(2):95-98, 2022. PMID: 35474723.
4. Davis JW . Behind the scenes. BJUI Compass 3(1):3-5, 2022. PMID: 35475159.
5. Davis JW . Editorial comment; on Successful same-day discharge for robot-assisted radical prostatectomy: a systematic review and meta-analysis. Urology Practice 9:304, 2022.
6. Davis JW . BJUI Compass 2021 year-end review. BJUI Compass 2(6):357-358, 2021. PMID: 35474699.
7. Davis JW . Chasing the elusive goal. BJUI Compass 2(5):303-305, 2021. PMID: 35474878.
8. Davis JW . A shout-out to middle authors: Opportunities for achieving clarity in editing. BJUI Compass 2(3):137-139, 2021. PMID: 35475130.
9. Davis JW . Editorial Comment. J Urol 205(4):1088, 2021. PMID: 33493000.
10. Davis JW . Eye of the beholder-Tales from Prostate Cancer Active Surveillance Development. BJUI Compass 2(2):67-70, 2021. PMID: 35474885.
11. Davis JW . The great escape: A tale of the visiting professor's Artful Dodge. BJUI Compass 2(1):3-6, 2021. PMID: 35474663.
12. Davis J.W. Seasonal events and journal milestones. BJUI Compass:3: 259-262, 2021.
13. Davis JW . Mr. Roboto (domo arigato, if you like). BJUI Compass 1(5):149-151, 2020. PMID: 35475211.
14. Davis JW . Four directions and four continents. BJUI Compass 1(3):85-86, 2020. PMID: 35474864.
15. Davis JW . BJUI Compass in the COVID era. BJUI Compass 1(2):43-44, 2020. PMID: 35474711.
16. Davis JW . Re: Medium-term Oncologic Outcomes in a Large Cohort of Men Treated with Focal or Hemi-ablation Using High-intensity Focused Ultrasonography for Primary Localized Prostate Cancer. Eur Urol 77(4):558, 2020. PMID: 32033840.
17. Davis JW . This issue in BJUI Compass: March 2020. BJUI Compass 1(1):3-4, 2020. PMID: 35474910.
18. Davis JW . Words of Wisdom: Re: Randomized compassion of techniques for control of the dorsal vein complex during robot-assisted laparoscopic radical prostatectomy. BJU Int:586-94, 2020.
19. Davis JW . Attention to detail. BJUI Compass:1: 119-121, 2020.
20. Dasgupta P, Davis JW . BJUI Compass and open access. BJU Int 124(5):713, 2019. PMID: 31646758.
21. Davis JW . AUA Publications: A Digital, Online and Interactive Future. J Urol 201(1):42-43, 2019. PMID: 30577386.
22. Dasgupta P, Davis JW , Hughes S. NICE guidelines on prostate cancer 2019. BJUI, 2019.
23. Sonier S, Simson N, Davis JW , Challacombe B. Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) vs standard RARP: It’s time for critical appraisal. BJU Int, 2018.
24. Davis JW . Biomarker classification, validation, and what to look for in 2017 and beyond. BJU Int 119(5):812-814, 2017. PMID: 28117555.
25. Davis JW - Guest Editor. International Prostate Forum Introduction and History - A Collection of 9 Articles with Editorial Comments. Asian Journal of Andrology 17(6):863, 2015.
26. Davis JW . Clever surgeons and challenging study endpoints. BJU Int 116(3):309, 2015. PMID: 26260418.
27. Davis JW . Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU Int 114(3):320-322, 2014. PMID: 25146527.
28. Davis JW . Robot-assisted prostatectomy in obese patients: how influential is obesity on operative outcomes?. J Endoruology, 2014.
29. Davis JW . Urological oncology in the BJUI. BJU Int 112(5):531-2, 2013. PMID: 23924417.
30. Davis JW , Choi S. Salvaging failed radiation therapy: does the tumour location permit a less toxic approach?. BJU Int 112(3):279-80, 2013. PMID: 23826837.
31. Davis JW , Editors Choice Comment, re: Eifler J, Feng Z, Lin B, et al. An updated prostate cancer staging nomogram (Partin Tables) based on cases from 2006-2011. BJU Int 111(3):524, 2013.
32. Davis JW , Dasgupta P. A case-mix-adjusted comparison of early oncologic outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int 111(2):184-5, 2013. PMID: 23356744.
33. Davis JW . What have we learned from the Partin table update?. BJU Int 111(1):5, 2013. PMID: 23323697.
34. Kim J, Davis JW . Prostate cancer screening-time to abandon one-size fits all approach?. JAMA 306(24):2717-8, 2011. PMID: 22203541.
35. Davis JW , Shih YC. Trends in the care of radical prostatectomy in the United States from 2003-2006. BJU Int 108(1):55, 2011. PMID: 21676146.
36. Davis JW . Screening for prostate cancer with serum prostate-specific antigen : what should we recommend while waiting for randomized clinical trial results?. Cancer 113(11):3067-8, 2008. PMID: 18932255.
37. Davis JW . Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: An Evaluation of analysis of health related quality of life in Japanese men with localized prostate cancer. J Urol 178:477, 2007.

Abstracts

1. Davis JW, Altok M.. Moderated Poster: Extended Pelvic Lymph Node Dissection for Intermediate - High Risk Prostate Cancer: A therapeutic uncertainty. American Urological Association 2016 Spring Meeting, San Diego, CA, 2016.
2. Davis JW, Achim M, Ward J, Pettaway C, Chapin B, Wang X, Kuban D, Frank S, Lee A, Pisters L, Matin S, Shah J, Karam J, Papadopoulos J, Hoffman K, Pugh T, Choi S, Logothetis C, Troncoso P, Kim J.. Active surveillance as initial management in men with phenotypically heterogenous early stage prostate cancer. Annual Meeting of the South Central Section, American Urological Association, 2014.
3. Nguyen J, Achim M, Chapin B, Matin S, Davis J.. Open or robot-assisted radical prostatectomy as the primary treatment of high risk prostate cancer: Oncologic outcomes and incidence of subsequent therapies. Annual Meeting of the South Central Section, American Urological Association, 2014.
4. Davis JW, Achim M, Ward J, Pettaway C, Chapin B, Wang X, Kuban D, Frank S, Lee A, Pisters L, Matin S, Shah J, Karam J, Papadopoulos J, Hoffman K, Pugh T, Choi S, Logothetis C, Troncoso P, Kim J.. Active surveillance as initial management in men with phenotypically heterogenous early stage prostate cancer. Annual Meeting of the American Society of Clinical Oncology, 2014.
5. Achim F, Chapin BF, Matin SF, Davis JW.. Open or robot-assisted radical prostatectomy as the primary treatment of high risk prostate cancer: Oncologic outcomes and incidence of subsequent therapies. World Congress of Endourology, New Orleans, LA, 2013.
6. Davis JW, Achim M, Matin SF.. Office-based assessment of quality of life after robot-assisted radical prostatectomy. Annual Meeting of the British Association of Urologic Surgeons, Manchester, UK, 2013.
7. Kim J, Ward JF, Pettaway CA, Wang X, Kuban DA, Frank SF, Lee A, Pisters LL, Matin SF, et al.. Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Journal of Clinical Oncol 31(15 (May 20/2013 suppl)):5069, 2013.
8. Davis JW, Kraeden U, Gabbert J, Thomas R. Robot-assisted radical prostatectomy: an administrative assessment of learning curve parameters. Annual Meeting of the American Urological Association, San Diego, CA, 2013.
9. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, et al.. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic Outcomes. Proceedings of 104th Annual Meeting of the American Association for Cancer Research, Washington, DC. Philadelphia, PA: AACR; Cancer Res 73(8):1538-7445, 2013.
10. Davis JW, Achim M, Matin SF.. Office-based assessment of quality of life after robot-assisted radical prostatectomy. 95th Annual American Radium Society, Scottsdale, Arizona, 2013.
11. Davis, JW, Achim M, Matin S, Babaian K, Troncoso P. Management of the Lymph Nodes after Robot-Assisted Radical Prostatectomy: a 4-Strategy Evaluation. 91st Annual Meeting of the South Central Section of the AUA, Colorado Springs, CO, 2012.
12. Achim M, Matin S, Pettaway C, Davis, JW. Robot-Assisted Radical Prostatectomy Training: 5-year Experience Using Time Metrics to Evaluate Progress. 91st Annual Meeting of the South Central Section of the AUA, Colorado Springs, CO, 2012.
13. Oh J, Davis J (Presenting), Hoffman K, Wen Sijin, Kim J. Significance of Age and Comorbidity in Management Decision-Making in Early Stage Prostate Cancer. 32nd Congress of the Societe Internationale d'Urologie, Fukuoka, Japan, 2012.
14. Efstathiou E, Davis J, Troncoso P, Titus M, Hoang A, Wen S, Zurita A, Tran N, Molina A, Logothetis C. Cytoreduction and androgen signaling modulation by abiraterone acetate plus leuprolide acetate (LHRHa) vs LHRHa in localized high risk cancer: preliminary results of a randomized prospective study. American Society of Clinical Oncology, Chicago, IL, 2012.
15. Davis J, Troncoso P, Meyer S, Day J, Groskopf J, Aubin S, Rodriguez Y, Lin D, Magi-Galluzzi C, Berglund R. Correlation of urine PCA3 score and TMPRSS2:ERG score with clinically significant tumor volume in radical prostatectomy specimens: Interim results form a multi-center prospective study. American Urological Association, Annual Meeting, Atlanta, GA, 2012.
16. Davis JW, Achim MF.. Nerve Sparing Radical Prostatectomy Planning using T2 Weighted Endorectal Coil MRI Imaging. European Association of Urology Annual Meeting-Vienna, Austria, 2011.
17. Davis, JW, Achim MF, Munsell M.. Extraperitoneal Access for Robot-Assisted Radical Prostatectomy: Assessment of Met and Unmet Needs of the Post-graduate Learning Curve. European Association of Urology Annual Meeting-Vienna, Austria, 2011.
18. Achim MF, Shah J, Davis JW,. Moderated Poster-High risk prostate cancer selected for radical prostatectomy: surgical planning with image guidance. South Central Section of the American Urological Association, 2010.
19. Davis JW, Shah J, Achim MF. Moderated Poster-high risk prostate cancer selected for robot-assisted radical prostatectomy: surgical planning with image guidance. World Congress of Endourology, 2010.
20. Davis JW. Moderated Poster- The Mimic DV Trainer TM: A Future Possibility for Surgical Training with Simulation. South Central Section of the American Urological Association, 2010.
21. Shih T, Ward J, Pettaway C, Xu Y, Thompson, B, Matin S, Davis JW. Etling L. Podium Abstract-Radical prostatectomy among prostate cancer patients in managed care organization; utilization, outcomes and costs. South Central Section of the American Urological Association, 2010.
22. Davis JW, Matin S, Babaian RJ, Pettaway C, Pisters L, Prokhorova I, Gonzales G, Munsell M, Troncoso P.. Podium Abstract-Comparative effectiveness of radical prostatectomy modalities: a focus on pathologic endpoints. South Central Section of the American Urological Association, 2010.
23. Shah B, Achim MF, Truong H, Davis JW.. Is more necessarily better?: standard versus extended pelvic lymph node dissection during robotic-assisted radical prostatectomy. American Urologic Association Annual Meeting 2010, 2010.
24. Davis JW, Troncoso P, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for localized prostate cancer-a prostate cancer-a prospective protocol. J Urol 181(4):494A, 2009.
25. Davis JW. Robot-assisted laparoscopic surgical management of high risk prostate cancer. J Urol 181(4):1018A, 2009.
26. Davis JW, Matin S.. Advanced robot-assisted laparoscopic prostatectomy training: building the foundation of a reproducible operation. Societe Internationale d'Urologie Oncology Update, 2008.
27. Davis JW. Robot-assisted surgical management of high-risk prostate cancer. Societe Internationale d'Urologie Oncology Update, 2008.
28. Davis JW, Kim J, Troncoso PT.. Radical Prostatectomy findings in patients considered potential candidates for active surveillance. Societe Internationale d'Urologie Oncology Update, 2008.
29. Davis JW, Troncoso PT, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetis C, Kim JW.. Active surveillance for clinically localized prostate cancer at a high volume tertiary referral center. Societe Internationale d'Urologie Oncology Update, 2008.
30. Davis JW, Dinney C, Grossman B, Kamat A,. Robotic-assisted laparoscopic surgery for invasive bladder cancer: can the lymph node dissection match the benchmarks of open surgeon's?. Societe Internationale d'Urologie Oncology Update, 2008.
31. Hubosky SG, Davis JW, Ball AJ, Given RW. Prospective, longitudinal, comparative study of health-related quality of life (QOL) in patients undergoing five different invasive treatments for localized prostate cancer: update 2005. Journal of Urology Annual Meeting 2006 Abstract 209, 2006.
32. Davis JW, Hubosky S, Given R, Lynch DF. The laparoscopic oncologist's dilemma: pure laparoscopic radical prostatectomy versus robotic assisted radical prostatectomy, and analysis of short term outcomes for a single institution. Journal of Urology Annual Meeting 2006 Abstract 1150, 2006.
33. Schellhammer PF, Diaz JI, Corica AG, Davis JW. Comparative assessment of open and laparoscopic prostatectomy by computer modeling technology. Journal of Urology 173/4:Abstract 693, 2005.
34. Ball AJ, Soderdahl DW, Davis JW, Schellhammer PF. Prospective, longitudinal, comparative study of health related quality of life in patients undergoing invasive treatments for localized prostate cancer: update 2004. Journal of Urology 173/4:Abstract 196, 2005.
35. Soderdahl DW, Fabrizio MD, Davis JW, Schellhammer PF. Prospective, longitudinal, comparative study of quality of life in patients undergoing invasive treatments for localized prostate cancer. Journal of Urology 171/4:Abstract 805, 2004.
36. El-Feel A, Davis JW, Deger S. Roigas J, Willie A, Schnorr D, Loening A, Tuerk IA. Positive margins following laparoscopic radical prostatectomy- a prospective analysis of 100 cases. European Urology 2/1:Abstract 394, 2003.
37. Davis JW, Richter F, Deger S, Roigas J, Willie A, Loening S, Tuerk IA. Laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ cell tumor: short term results from a high volume laparoscopy center. European Urology 2/1:Abstract 186, 2003.
38. El-Feel A, Davis JW, Deger S, Roigas J, Wille A, Schnorr D, Loening SA, Tuerk IA. Learning curve for laparoscopic radical prostatectomy: a prospective analysis of 100 cases. European Urology 2/1:Abstract 179, 2003.
39. Tuerk IA, Fabrizio MD, Deger S, Davis JW, Winckelmann B, Schellhammer PF, Loenig SA. Laparoscopic radical prostatectomy-the combined experience from Berlin and Norfolk with 308 patients. Abstract 1352, J Urology Annual Meeting 2002, 2002.
40. McAdams P, Davis JW, Rovey E, Doviak MJ, Schellhammer PF. High-risk prostate cancer treated by radiation therapy: does laparoscopic pelvic lymph node staging improve five-year biochemical disease-free outcome?. Abstract 919, J Urology Annual Meeting 2002, 2002.
41. Adam BL, Davis JW, Ward MB, Clement MA, Cazares LH, Vlahou A, Semmes OJ, Schellhammer PF, Dalmasso E, Yingsheng Q, Yasui Y, Feng Z, Wright GL. Protein profiling combined with a decision tree algorithm discriminates prostate cancer from benign prostate hyperplasia and unaffected men. Abstract LB15, American Urological Association Meeting 2002, 2002.
42. Tuerk IA, Davis JW, Deger S, Winckelmann B, Schellhammer PF, Loening SA. Follow-up after laparoscopic radical cystectomy and intracorporeal constructed rectum-sigma pouch (Mainz POuch II). Abstract 237, J Urology Annual Meeting 2002, 2002.
43. Davis JW, Adam BL, Ward MD, Clements MA, Cazares LH, Yasui Y, Qu Y, Feng Z, Dalmasso E, Schellhammer PF, Wright GL. Protein profiling of seminal plasma and serum using Ciphergen's SELDI ProteinChip® technology for early detection of prostate cancer. Abstract 840, American Urological Association Meeting 2001, 2001.
44. Davis JW, Clements MA, Brassil D, Doviak MJ, Wright GL, Schellhammer PF. Recovery of serum testosterone after brachytherapy with neoadjuvant androgen deprivation for localized prostate cancer. Abstract 1344, American Urological Association Meeting 2001, 2001.
45. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF. High risk or recurrent superficial bladder carcinoma treated with BCG: Progression free and disease specific survival with minimum 10 year follow-up. Abstract 777, American Urological Association Meeting 2001, 2001.
46. Davis JW, Kuban D, Lynch DF, Schellhammer PF. Quality of life after radical prostatectomy vs. brachytherapy for localized prostate cancer. American Society of Therapeutic Radiation Oncology Annual Meeting, 2000, 2000.
47. Davis JW, Adam BL, Clements MA, Cazares LH. Detection of Prostate Cancer Associated Proteins in Body Fluids using Ciphergen's SELDI™ ProteinChip®Technology. 1st Annual Meeting of the NCI's Early Detection Research Network-Chicago, IL 2000, 2000.
48. Davis JW, Kuban D, Lynch DF, Schellhammer PF. Quality of life after radical prostatectomy vs. brachytherapy for localized prostate cancer. Abstract 1272, American Urological Association Meeting, 2000, 2000.
49. Adam BL, Davis JW, Xia Z, Cazares LH, Schellhammer PF, Wright GL Jr.. Simultaneous Measurement of Free, Complexed and Total PSA using a Novel Biochip Multiplex SELDI Mass Spectrometry Immunoassay. American Urological Association Meeting, 2000, 2000.

Book Chapters

1. Davis, JW. Surgeon’s Notebook: Beyond the Learning Curve: The Original Handouts from the American Urological Association Postgraduate Courses 2013-2015,” “The Simple Bladder Neck,” “Pelvic Lymph Node Dissection: Robotic Surgery Efficiency and Space-Creation Techniques to Achieve an Extended Template,” “Personalized versus Generic Patient handouts: Tools to Improve Patient Knowledge on Treatment Options and Perioperative Care. In: Robot Assisted Radical Prostatectomy—Beyond the Learning Curve, 2016.
2. Davis JW, Mmeje C. Leading-edge Diagnostic Procedures and Treatments, Prof. Ravinder Mohan. In: Advances in Prostate Cancer Diagnosis: Triggers for Prostate Biopsy, Prostate Cancer. (Ed.), InTech, DOI, 2016.
3. Gaston KE, Davis JW. Robot-Assisted Pelvic Lymphadenectomy. In: Robotic Surgery of the Bladder, 93-101, 2014.
4. Pettaway CA, Lance RS, Davis JW. Tumors of the Penis. In: Campbell-Walsh Urology. 10th. Saunders Elsevier, 2012.
5. Patterson M, Davis JW, Kim J, Hoffman. Genitourinary Cancer Survivorship Management. In: Cancer Survivorship, Internal MDACC Project. TBA, 2011.
6. Logothetis CJ, Kim J, Davis J, Kuban D, Mathew P, Aparico A. Neoplasms of the Prostate. In: Cancer Medicine. 8th. Peoples Medical Publishing House-USA: Shelton, CONN, 1228-1254, 2010.
7. Bianco F, Davis JW. Complications after Robot Assisted Radical Cystectomy with Urinary Diversion: New Approach Same Old Foe. In: Textbook of Robotic Surgery, 2010.
8. Davis JW, Shaves M, Schellhammer PH. Management of Locally Advanced and Metastatic Disease. In: International Handbook of Prostate Cancer. 3rd. Euromed Communications, Ltd: Haslemere, England, 183-202, 2008.
9. Pettaway CA, Lynch DF, Davis JW. Tumors of the Penis. In: Campbell-Walsh Urology. 9th. Saunders Elsevier, 959-992, 2007.
10. Davis JW, Schellhammer PF. Clinical Signs and Symptoms of Prostate Cancer. In: Comprehensive Textbook of Genitourinary Oncology. 3rd. Lippincott Williams and Wilkins, 2006.
11. Davis JW, Tuerk IA, Deger S, Loening SA. Minimally invasive treatments for bladder cancer- from transurethral resection to laparoscopic radical cystectomy. In: Minimally Invasive Urologic Surgery. Taylor and Francis, 2005.
12. Davis JW, Tuerk IA, Deger S, Loening SA. Minimally invasive treatments for bladder cancer-from transurethral resection to laparoscopic radical cystectomy. In: Minimally Invasive Uro-Oncologic Surgery. Taylor and Francis, 2005.
13. Davis JW, Schellhammer PF. Quality of Life: impact of prostate cancer and its treatment. In: Prostate Cancer: Science and Clinical Practice. Academic Press, 2003.
14. Davis JW, Schellhammer PF. Radical Retropubic Prostatectomy. In: Prostate Cancer: Science and Clinical Practice. Academic Press, 2003.
15. Davis JW, Lynch DF. Penile Cancer. In: Urology Pearls of Wisdom. Boston Medical Publishers: Boston, 2001.
16. Baltimore, Williams and Wilkins. Thyroid, Melanomas, Sarcomas, Lymphomas, and Common Surgical Medications. In: Blackbourne, Surgical Recall, 1994.

Books (edited and written)

1. Davis JW, et al.. Robot-Assisted Radical Prostatectomy: Beyond the Learning Curve. In: Springer. Ed(s) Davis JW. 1st. Springer International Publishing AG, Cham. 2016.